1 rotection, generated the enantiomers of 2,2'-LBPA.

2 omal phospholipid lyso-bisphosphatidic acid (LBPA) (also known as bismonoacylglycerol phosphate).

3 omal phospholipid lyso-bisphosphatidic acid (LBPA), suggesting an important role for LBPA in NPC2-med

4  endosomal marker lyso-bisphosphatidic acid (LBPA).

5  analogue of (S,S)-lysobisphosphatidic acid (LBPA) and its enantiomer were synthesized from the same

6  It was found that lysobisphosphatidic acid (LBPA) is required for release of PS-ASOs from LEs.

7 ntiomerically pure lysobisphosphatidic acid (LBPA), bisether analogues, and phosphorothioate analogue

8                      Inside LEs, PS-ASOs and LBPA were co-localized in punctate, dot-like structures,

9              Deactivation of LBPA using anti-LBPA antibody significantly decreased PS-ASO activities

10      The (R,R) and (S,S) enantiomers of both LBPA and phosphorothioate LBPA were synthesized from (S)

11 n properties of ILVs, which are supported by LBPA, contribute to PS-ASO intracellular release from LE

12        Furthermore, Alix reduction decreased LBPA levels and limited co-localization of LBPA with PS-

13 cid (LBPA), suggesting an important role for LBPA in NPC2-mediated cholesterol trafficking.

14 analogues, and phosphorothioate analogues of LBPA from solketal.

15                              Deactivation of LBPA using anti-LBPA antibody significantly decreased PS

16 d LBPA levels and limited co-localization of LBPA with PS-ASOs at ILVs inside LEs.

17 e recycling, EGFR accumulates in a subset of LBPA-rich perinuclear multivesicular bodies (MVBs) disti

18 CRT complex, the unconventional phospholipid LBPA, and other known endocytosis regulators.

19 nantiomers of both LBPA and phosphorothioate LBPA were synthesized from (S)- and (R)-solketal, respec

20 internalization and became co-localized with LBPA by 2 hours in LEs.